Bristol-Myers Squibb Company (BMY) : The consensus price target for Bristol-Myers Squibb Company (BMY) is $68.39 for the short term with a standard deviation of $12.94. The most optimist securities analyst among the 13 who monitor the stock believes that the stock can reach $100, however, the pessimist price target for the company is $48.
Bristol-Myers Squibb Company (BMY) has an average broker rating of 2.65, which is interpreted as a Hold, as rated by 17 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 10 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 2 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.
Also, UBS maintains their rating on the shares of Bristol-Myers Squibb Company (NYSE:BMY). The current rating of the shares is Buy. Equity Analysts at the Firm lowers the price target to $70 per share from $80 per share. The rating by the firm was issued on August 19, 2016.
Bristol-Myers Squibb Company (NYSE:BMY): The stock opened at $57.60 on Thursday but the bulls could not build on the opening and the stock topped out at $57.62 for the day. The stock traded down to $56.49 during the day, due to lack of any buying support eventually closed down at $56.76 with a loss of -1.10% for the day. The stock had closed at $57.39 on the previous day. The total traded volume was 12,873,853 shares.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.